Literature DB >> 32265213

Aggressive presentation of plasmablastic myeloma.

Jaime Andres Suarez-Londono1, Abhinav Rohatgi1, Crystal Antoine-Pepeljugoski1, Marc J Braunstein2.   

Abstract

Entities:  

Keywords:  haematology (incl blood transfusion); malignant disease and immunosuppression; oncology

Mesh：

Substances：

Year:  2020        PMID： 32265213      PMCID： PMC7244288          DOI： 10.1136/bcr-2020-234436

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


× No keyword cloud information.
  3 in total

Review 1.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

2.  Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.

Authors:  P R Greipp; T Leong; J M Bennett; J P Gaillard; B Klein; J A Stewart; M M Oken; N E Kay; B Van Ness; R A Kyle
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

3.  Multiple myeloma: significance of plasmablastic subtype in morphological classification.

Authors:  P R Greipp; N M Raymond; R A Kyle; W M O'Fallon
Journal:  Blood       Date:  1985-02       Impact factor: 22.113
  3 in total
  3 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

2.  Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.

Authors:  Bo-Jung Chen; Chang-Tsu Yuan; Ching-Fen Yang; Chung-Han Ho; Yen-Kuang Lin; Ying-Zhen Su; Hsiu-Chu Chou; Shih-Sung Chuang
Journal:  Virchows Arch       Date:  2022-06-03       Impact factor: 4.535

3.  Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.

Authors:  Matthew Lee; Beth A Martin; Haifaa Abdulhaq
Journal:  Case Rep Hematol       Date:  2022-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.